Evidence map›Paper›PMID 37480088›Full record

ArticleAlzheimer's research & therapy2023

Alzheimer's pathology is associated with altered cognition, brain volume, and plasma biomarker patterns in traumatic encephalopathy syndrome.

Breton M Asken, Jeremy A Tanner, Leslie S Gaynor, Lawren VandeVrede, William G Mantyh, Kaitlin B Casaletto, Adam M Staffaroni, Corrina Fonseca, Ranjani Shankar, Harli Grant and 13 more

Open access · goldAbstract read
In one paragraph

Article in Alzheimer's research & therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Observational
  5. Article
  6. Article
  7. CTE neuropathology alone is associated with dementia and cognitive symptoms.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Alzheimer's & dementia (Amsterdam, Netherlands)
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 7 institutions in 2 countries.

Breton M AskenDepartment of Clinical & Health Psychology, 1Florida Alzheimer's Disease Research Center, University of Florida, 1225 Center Drive, Gainesville, FL, 32610, USA. basken8@phhp.ufl.edu.
Jeremy A TannerDepartment of Neurology, Biggs Institute for Alzheimer's and Neurodegenerative Diseases, South Texas Alzheimer's Disease Research Center, University of Texas Health - San Antonio, 7703 Floyd Curl Drive, San Antonio, TX, 78229, USA.
Leslie S GaynorDepartment of Neurology, Weill Institute for Neurosciences, Memory and Aging Center, University of California, San Francisco, 675 Nelson Rising Lane, San Francisco, CA, 94158, USA.
Lawren VandeVredeDepartment of Neurology, Weill Institute for Neurosciences, Memory and Aging Center, University of California, San Francisco, 675 Nelson Rising Lane, San Francisco, CA, 94158, USA.
William G MantyhDepartment of Neurology, University of Minnesota, PWB 12-100, 516 Delaware Street SE, Minneapolis, MN, 55455, USA.
Kaitlin B CasalettoDepartment of Neurology, Weill Institute for Neurosciences, Memory and Aging Center, University of California, San Francisco, 675 Nelson Rising Lane, San Francisco, CA, 94158, USA.
Adam M StaffaroniDepartment of Neurology, Weill Institute for Neurosciences, Memory and Aging Center, University of California, San Francisco, 675 Nelson Rising Lane, San Francisco, CA, 94158, USA.
Corrina FonsecaDepartment of Neuroscience, Helen Wills Neuroscience Institute, University of California, 132 Barker Hall MC#3190, Berkeley, CA, 94720, USA.
Ranjani ShankarDepartment of Neurology, Weill Institute for Neurosciences, Memory and Aging Center, University of California, San Francisco, 675 Nelson Rising Lane, San Francisco, CA, 94158, USA.
Harli GrantDepartment of Neurology, Weill Institute for Neurosciences, Memory and Aging Center, University of California, San Francisco, 675 Nelson Rising Lane, San Francisco, CA, 94158, USA.
Karen SmithDepartment of Neurology, Weill Institute for Neurosciences, Memory and Aging Center, University of California, San Francisco, 675 Nelson Rising Lane, San Francisco, CA, 94158, USA.
Argentina Lario LagoDepartment of Neurology, Weill Institute for Neurosciences, Memory and Aging Center, University of California, San Francisco, 675 Nelson Rising Lane, San Francisco, CA, 94158, USA.
Haiyan XuDepartment of Surgery, University of Florida, PO Box 100128, Gainesville, FL, 32610, USA.
Renaud La JoieDepartment of Neurology, Weill Institute for Neurosciences, Memory and Aging Center, University of California, San Francisco, 675 Nelson Rising Lane, San Francisco, CA, 94158, USA.
Yann CobigoDepartment of Neurology, Weill Institute for Neurosciences, Memory and Aging Center, University of California, San Francisco, 675 Nelson Rising Lane, San Francisco, CA, 94158, USA.
Howie RosenDepartment of Neurology, Weill Institute for Neurosciences, Memory and Aging Center, University of California, San Francisco, 675 Nelson Rising Lane, San Francisco, CA, 94158, USA.
David C PerryDepartment of Neurology, Weill Institute for Neurosciences, Memory and Aging Center, University of California, San Francisco, 675 Nelson Rising Lane, San Francisco, CA, 94158, USA.
Julio C RojasDepartment of Neurology, Weill Institute for Neurosciences, Memory and Aging Center, University of California, San Francisco, 675 Nelson Rising Lane, San Francisco, CA, 94158, USA.
Bruce L MillerDepartment of Neurology, Weill Institute for Neurosciences, Memory and Aging Center, University of California, San Francisco, 675 Nelson Rising Lane, San Francisco, CA, 94158, USA.
Raquel C GardnerSheba Medical Center, Tel Hashomer City of Health, Tel Aviv District, Derech Sheba 2, Ramat Gan, Israel.
Kevin K W WangDepartment of Neurobiology, Morehouse School of Medicine, 720 Westview Drive SW, Atlanta, GA, 30310, USA.
Joel H KramerDepartment of Neurology, Weill Institute for Neurosciences, Memory and Aging Center, University of California, San Francisco, 675 Nelson Rising Lane, San Francisco, CA, 94158, USA.
Gil D RabinoviciDepartment of Neurology, Weill Institute for Neurosciences, Memory and Aging Center, University of California, San Francisco, 675 Nelson Rising Lane, San Francisco, CA, 94158, USA.
University of California, San Francisco · USMorehouse School of Medicine · USSheba Medical Center · ILThe University of Texas Health Science Center at San Antonio · USUniversity of Florida · USUniversity of Florida Health · USUniversity of Minnesota · US

Funding

TDP-43 Loss-of-Function: Biology to BiomarkersP01AG019724 · NIA · UNIVERSITY OF PENNSYLVANIA · PI Jennifer Merrilees · 2002 to 2026
$67.2M
Research Education ComponentP30AG062422 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Gil Dan Rabinovici · 2019 to 2026
$36.9M
Mechanisms of Executive Decline in Normal AgingR01AG032289 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Kaitlin B Casaletto, JOEL H KRAMER · 2009 to 2026
$8.3M
Biological Predictors Of Brain Aging Trajectories Diversity Supplement: African American Outreach And The Intersection Between Social Determinants Of Health And Biomarkers Of Degenerative DiseaseRF1AG032289 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KRAMER, JOEL H · 2020 to 2021
$5.3M
Reimagining Precision Medicine Approaches to AD DiagnosisR35AG072362 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI POSSIN, KATHERINE LAUREL, RABINOVICI, GIL DAN · 2021 to 2025
$4.8M
Unraveling the intersection of synaptic biology, lifestyle, and cognitive resilienceR01AG072475 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CASALETTO, KAITLIN B · 2021 to 2025
$4.3M
Diagnostic and prognostic certainty in behavioral variant frontotemporal dementiaR01AG062758 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PERRY, DAVID C · 2020 to 2025
$4.0M
Dementia prevalence, APOE, and blood-based biomarkers of AD in Native American communitiesR01AG080806 · NIA · UNIVERSITY OF MINNESOTA · PI William G Mantyh · 2022 to 2026
$3.7M
Transforming Research And Clinical Knowledge in Geriatric Traumatic Brain Injury (TRACK-GERI)R01NS110944 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GARDNER, RAQUEL C., MANLEY, GEOFFREY T · 2019 to 2023
$3.4M
Effects of chronic inflammation on brain structure and functionR01AG048234 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KRAMER, JOEL H · 2015 to 2019
$3.2M
Early Age-of-Onset AD: Clinical Heterogeneity and Network DegenerationR01AG045611 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI RABINOVICI, GIL DAN · 2014 to 2018
$3.1M
Validation of Novel Plasma Biomarkers for Mixed Etiology DementiaK23AG073514 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI VANDEVREDE, LAWREN · 2021 to 2025
$1.0M
NIA NIH HHS K23 AG059888NIA NIH HHS K23 AG061253NIA NIH HHS K23 AG073514NIA NIH HHS K99 AG065501NIA NIH HHS L30 AG069301NIA NIH HHS P01 AG019724NIA NIH HHS P30 AG062422NIA NIH HHS R01 AG032289NIA NIH HHS R01 AG045611NIA NIH HHS R01 AG048234NIA NIH HHS R01 AG062758NIA NIH HHS R01 AG072475NIA NIH HHS R01 AG080806NIA NIH HHS R35 AG072362NIA NIH HHS RF1 AG032289NINDS NIH HHS R01 NS110944
6 · The paper itself

Abstract

backgroundTraumatic encephalopathy syndrome (TES) is a clinical phenotype sensitive but non-specific to underlying chronic traumatic encephalopathy (CTE) neuropathology. However, cognitive symptoms of TES overlap with Alzheimer's disease (AD), and features of AD pathology like beta-amyloid (Aβ) plaques often co-occur with CTE, making clinical-to-pathological conclusions of TES diagnoses challenging. We investigated how Alzheimer's neuropathological changes associated with cognition, brain volume, and plasma biomarkers in patients with repetitive head impacts (RHI)/TES, clinical AD, or typically aging controls.

methodsWe studied 154 participants including 33 with RHI/TES (age 61.5 ± 11.5, 100% male, 11/33 Aβ[ +]), 62 with AD and no known prior RHI (age 67.1 ± 10.2, 48% male, 62/62 Aβ[ +]), and 59 healthy controls without RHI (HC; age 73.0 ± 6.2, 40% male, 0/59 Aβ[ +]). Patients completed neuropsychological testing (memory, executive functioning, language, visuospatial) and structural MRI (voxel-based morphometry analysis), and provided plasma samples analyzed for GFAP, NfL, IL-6, IFN-γ, and YKL-40. For cognition and plasma biomarkers, patients with RHI/TES were stratified as Aβ[ +] or Aβ[ -] and compared to each other plus the AD and HC groups (ANCOVA adjusting for age and sex). Differences with at least a medium effect size (Cohen's d > 0.50) were interpreted as potentially meaningful.

resultsCognitively, within the TES group, Aβ[ +] RHI/TES performed worse than Aβ[-] RHI/TES on visuospatial (p = .04, d = 0.86) and memory testing (p = .07, d = 0.74). Comparing voxel-wise brain volume, both Aβ[ +] and Aβ[ -] RHI/TES had lower medial and anterior temporal lobe volume than HC and did not significantly differ from AD. Comparing plasma biomarkers, Aβ[ +] RHI/TES had higher plasma GFAP than HC (p = .01, d = 0.88) and did not significantly differ from AD. Conversely, Aβ[ -] RHI/TES had higher NfL than HC (p = .004, d = 0.93) and higher IL-6 than all other groups (p's ≤ .004, d's > 1.0).

conclusionsPresence of Alzheimer's pathology in patients with RHI/TES is associated with altered cognitive and biomarker profiles. Patients with RHI/TES and positive Aβ-PET have cognitive and plasma biomarker changes that are more like patients with AD than patients with Aβ[ -] RHI/TES. Measuring well-validated Alzheimer's biomarkers in patients with RHI/TES could improve interpretation of research findings and heighten precision in clinical management.

Indexed as

Alzheimer DiseaseBrain Injuries, TraumaticChronic Traumatic EncephalopathyBiomarkersBrainCognitionFemaleHumansInterleukin-6MaleBiomarkersInterleukin-6AmyloidBiomarkerBrain injuryChronic traumatic encephalopathyGFAPNfLPETPlasmaRepetitive head impactsTraumatic encephalopathy syndrome

Identifiers

PMID37480088
PMCPMC10360257
OpenAlexW4385064618

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.